Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Single-Center, Open-Label, Single-Arm Safety, Tolerability, and Efficacy Study of an Auricle and Wedge Subcutaneous Implant Combination Product (AUR-201) in Patients With Unilateral Microtia

NCT06225336 is registered in ClinicalTrials.gov with Auregen Biotherapeutics, SA as lead sponsor.

NCT NCT06225336
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06225336 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Single-Center, Open-Label, Single-Arm Safety, Tolerability, and Efficacy Study of an Auricle and Wedge Subcutaneous Implant Combination Product (AUR-201) in Patients With Unilateral Microtia
Lead sponsor
Auregen Biotherapeutics, SA
Phase
Phase 1
Overall status
Terminated
Start date
November 4, 2022
Completion date
September 10, 2025
Enrollment
2 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

microtia